The ability of T-cells, which are present in many tumours, will be exploited to destroy tumour cells. Boosting patients’ immune responses to tumours and the application of genetically engineered T cells in trials are some of the strategies employed.

We are focusing on CAR-T cell therapy to reprogramme T cells to recognise and kill tumour cells; checkpoint inhibitor therapy to help the body recognise and attack cancer cells; and neo-antigen T-cell therapy to generate anti-tumour immune responses by manufacturing individual patient tumour-specific T-cells.

Underlying these strategies, investments have been made in cutting edge imaging, molecular profiling and facilities for early phase clinical trials. Our research is primarily focused on those malignancies in which there are clinical strengths reinforced by dedicated laboratory programmes at UCL and UCLH.